<DOC>
	<DOCNO>NCT02968810</DOCNO>
	<brief_summary>This randomized phase II trial study well simvastatin work prevent liver cancer patient liver cirrhosis . Simvastatin may stop growth cancer cell block enzymes need cell growth .</brief_summary>
	<brief_title>Simvastatin Preventing Liver Cancer Patients With Liver Cirrhosis</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate effect simvastatin intervention versus placebo change serum AFP-L3 % baseline 6 month follow treatment initiation patient liver cirrhosis current model end-stage liver disease ( MELD ) = &lt; 20 . SECONDARY OBJECTIVES : I . To evaluate effect simvastatin intervention versus placebo 6 month baseline change serum AFP . II . To evaluate effect simvastatin intervention versus placebo 6 month baseline change serum IL-6 . III . To evaluate effect simvastatin intervention versus placebo 6 month baseline change serum bile acid level . IV . To evaluate effect simvastatin intervention versus placebo 6 month baseline change liver stiffness . V. To evaluate effect simvastatin intervention versus placebo 6 month baseline change fibrosis 4 index ( FIB-4 ) score . VI . To evaluate effect simvastatin intervention versus placebo 6 month baseline change MELD score . OUTLINE : Patients randomize 1 2 group . GROUP I : Patients receive simvastatin orally ( PO ) daily ( QD ) . GROUP II : Patients receive placebo PO QD . In group , treatment continue 6 month absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 , 60 , 90 day .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Confirmed diagnosis liver cirrhosis assess presence clinical sign , symptom , body imaging ( ultrasound , compute tomography [ CT ] , magnetic resonance image [ MRI ] ) , liver biopsy Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 ( Karnofsky &gt; = 70 % ) Leukocytes &gt; = 2,500/microliter Absolute neutrophil count &gt; = 1,500/microliter Platelets &gt; = 100,000/microliter Hemoglobin within normal institutional limit Total bilirubin = &lt; 1.5 x institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamicoxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 3 x institutional ULN Creatinine within normal institutional limit Women able become pregnant must confirm negative pregnancy test result prior enrollment Women able become pregnant must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform study physician immediately Ability understand willingness sign write informed consent document medical release Willing able comply trial protocol followup Prior current use statin medication Current use medication know interact statin potentially increase toxicity , include gemfibrozil , cyclosporine , danazol , lomitapide , verapamil , diltiazem , dronedarone , amiodarone , amlodipine , ranolazine , strong CYP3A4 inhibitor ( e.g. , itraconazole , ketoconazole , posaconazole , voriconazole , HIV protease inhibitor , boceprevir , telaprevir , erythromycin , clarithromycin , telithromycin , nefazodone , cobicistatcontaining product ) , strong CYP3A4 inducer ( e.g. , carbamazepine , phenytoin , rifampin , St. John 's wort , bosentan , efavirenz , etravirine , modafinil , nafcillin ) History adverse effect , intolerance , allergic reaction attribute compound similar chemical biologic composition simvastatin ( i.e. , statin medication ) Current use investigational agent Women pregnant breastfeeding ; breastfeed discontinue mother treated simvastatin Prior liver transplant Prior know suspect hepatocellular carcinoma Prior cholangiocarcinoma Model endstage liver disease ( MELD ) &gt; 20 ALT AST &gt; 3 x institutional ULN Decompensated liver cirrhosis acute liver failure Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement History chronic myopathy Prior germ cell cancer History active malignancy ( exclude basal/squamous cell skin cancer ) Known active infection human immunodeficiency virus ( HIV ) Medical contraindication blood draw ( e.g. , hemophilia ) Concurrent illness opinion investigator would compromise either patient integrity data Excessive alcohol consumption ( average alcohol consumption 5 drink per day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>